<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10989013</article-id><article-id pub-id-type="pmcid-ver">PMC10989013.1</article-id><article-id pub-id-type="pmcaid">10989013</article-id><article-id pub-id-type="pmcaiid">10989013</article-id><article-id pub-id-type="pmid">38411988</article-id><article-id pub-id-type="doi">10.1128/aac.01663-23</article-id><article-id pub-id-type="publisher-id">01663-23</article-id><article-id pub-id-type="publisher-id">aac.01663-23</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Therapeutics</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">antimicrobial-chemotherapy</compound-subject-part><compound-subject-part content-type="label">Antimicrobial Chemotherapy</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Impact of hypoalbuminemia on clinical outcomes among patients with obesity treated with ceftriaxone</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0200-1782</contrib-id><name name-style="western"><surname>Arensman Hannan</surname><given-names initials="K">Kellie</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/><email>hannan.kellie@mayo.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Draper</surname><given-names initials="E">Evan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cole</surname><given-names initials="KC">Kristin C.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mc Hugh</surname><given-names initials="J">Jack</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8308-3264</contrib-id><name name-style="western"><surname>Rivera</surname><given-names initials="CG">Christina G.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abu Saleh</surname><given-names initials="O">Omar</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Department of Pharmacy, Mayo Clinic Health System</institution></institution-wrap>, <city>Mankato</city>, <state>Minnesota</state>, <country>USA</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>Department of Pharmacy, Mayo Clinic</institution></institution-wrap>, <city>Rochester</city>, <state>Minnesota</state>, <country>USA</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution>Department of Quantitative Health Sciences, Mayo Clinic</institution></institution-wrap>, <city>Rochester</city>, <state>Minnesota</state>, <country>USA</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution>Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic</institution></institution-wrap>, <city>Rochester</city>, <state>Minnesota</state>, <country>USA</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Leggett</surname><given-names initials="JE">James E.</given-names></name><aff><institution-wrap><institution>Providence Portland Med Ctr</institution></institution-wrap>, <city>Portland</city>, <country>USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Kellie Arensman Hannan, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:hannan.kellie@mayo.edu">hannan.kellie@mayo.edu</email></corresp><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>4</month><year>2024</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>27</day><month>2</month><year>2024</year></pub-date><volume>68</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">459202</issue-id><elocation-id>e01663-23</elocation-id><history><date date-type="received"><day>15</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>07</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-06 00:25:33.900"><day>06</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 American Society for Microbiology.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>American Society for Microbiology.</copyright-holder><license><ali:license_ref specific-use="version-of-record">https://doi.org/10.1128/ASMCopyrightv2</ali:license_ref><license-p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1128/ASMCopyrightv2">All Rights Reserved</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="aac.01663-23.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="aac.01663-23.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="letter" journal-id="Antimicrob Agents Chemother" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11620499"><article-title>Possibility of hypoalbuminemia itself as a risk for clinical failure</article-title><volume>68</volume><issue>6</issue><date><day>17</day><month>4</month><year>2024</year></date><elocation-id>e00367-24</elocation-id><source>Antimicrobial Agents and Chemotherapy</source><pub-id pub-id-type="doi">10.1128/aac.00367-24</pub-id><pub-id pub-id-type="pmcid">PMC11620499</pub-id><pub-id pub-id-type="pmid">38629859</pub-id></related-article><abstract abstract-type="primary"><title>ABSTRACT</title><p>The use of ceftriaxone, a highly protein-bound drug, in the setting of hypoalbuminemia may result in suboptimal drug exposure. Patients with obesity also exhibit higher absolute drug clearance. We aimed to evaluate the impact of hypoalbuminemia on clinical success among hospitalized adults with obesity who were treated with ceftriaxone. This retrospective review included adult inpatients with weight &gt;100 kg or body mass index &gt;40 kg/m<sup>2</sup> who received ceftriaxone 2 g intravenously every 12 hours for at least 72 hours. The primary outcome was clinical success, a composite of clinical cure and microbiologic cure. Secondary outcomes included clinical cure, microbiologic cure, length of stay, ICU length of stay, mortality, 30-day readmission, and adverse events. In all, 137 patients were included, 34 of whom had a serum albumin of &#8804;2.5 g/dL. In a propensity-score-weighted analysis, clinical success was significantly more common among those without hypoalbuminemia (91.2%) as compared to those with hypoalbuminemia (77.8%) (<italic toggle="yes">P</italic> = 0.038). Death within 30 days (13.7% vs 0%, <italic toggle="yes">P</italic> &lt; 0.001) and 30-day readmission (31.6% vs 12.0%, <italic toggle="yes">P</italic> = 0.008) were more common in the hypoalbuminemia group. In a univariate analysis, serum albumin and indication for ceftriaxone use were found to be predictors of clinical success. Hypoalbuminemia was associated with a lower rate of clinical success among patients with obesity who were treated with ceftriaxone 2 g every 12 hours.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>ceftriaxone</kwd><kwd>hypoalbuminemia</kwd><kwd>pharmacokinetics</kwd><kwd>PK/PD</kwd><kwd>obesity</kwd></kwd-group><counts><count count="0" count-type="supplementary-material"/><count count-type="authors" count="6"/><table-count count="4"/><ref-count count="24"/><page-count count="7"/><word-count count="4247"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2024</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>